Actualités Pharma Equity Group A/s - 0REU | Actions London Stock Exchange

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

Notice convening the extraordinary general meeting of Pharma Equity Group A/S 8 May 2024 Announcement no. 15 Notice convening the extraordinary...

Major shareholder announcement - Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S Major shareholder announcement - Pharma Equity Group A/S 23 April 2024Company...

Passing of the General Meeting of Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S Passing of the General Meeting of Pharma Equity Group A/S 16 April 2024Company...

The Board of Director's decision to issue convertible loans

The Board of Director's decision to issue convertible loans The Board of Director's decision to issue convertible loans 10 April...

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the...

Notice convening the annual general meeting in Pharma Equity Group A/S

Notice convening the annual general meeting in Pharma Equity Group A/S 25 March 2024 Announcement no. 10 Notice convening the annual general...

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009...

Completion of subscription of convertible loans

Completion of subscription of convertible loans Completion of subscription of convertible loans March 21, 2024Company...

Pharma Equity Group A/S - Annual Report 2023

Pharma Equity Group A/S - Annual Report 2023 Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7...

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the...

Completion of subscription of convertible loans

Completion of subscription of convertible loans 7 February 2024 Company Announcement No. 05 Completion of subscription of convertible loans On 7...

The Board of Director's decision to issue convertible loans

The Board of Director's decision to issue convertible loans The Board of Director's decision to issue convertible loans 7 February...

Completion of subscription of convertible loans

Completion of subscription of convertible loans 25 January 2024 Company Announcement No. 03 Completion of subscription of convertible loans On 22...

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate...

The Board of Director's decision to issue convertible loans

The Board of Director's decision to issue convertible loans The Board of Director's decision to issue convertible loans 22 January...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharma Equity Group A/s (0REU)

Votre Hub pour des idées et discussions en direct en temps réel

0REU Actualités

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S

The Board of Director's decision to issue convertible loans

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Completion of subscription of convertible loans

Pharma Equity Group A/S - Annual Report 2023

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Completion of subscription of convertible loans

The Board of Director's decision to issue convertible loans

Completion of subscription of convertible loans

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

The Board of Director's decision to issue convertible loans

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharma Equity Group A/s (0REU) Actualités

Pharma Equity Group A/s (0REU)

Votre Hub pour des idées et discussions en direct en temps réel

0REU Actualités

Notice convening the extraordinary general meeting of Pharma Equity Group A/S

Major shareholder announcement - Pharma Equity Group A/S

Passing of the General Meeting of Pharma Equity Group A/S

The Board of Director's decision to issue convertible loans

Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051.

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009

Completion of subscription of convertible loans

Pharma Equity Group A/S - Annual Report 2023

Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).

Completion of subscription of convertible loans

The Board of Director's decision to issue convertible loans

Completion of subscription of convertible loans

Notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions aiming to eliminate bacterial promoters of colorectal cancer through intraluminal application (RNX-051).

The Board of Director's decision to issue convertible loans

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres